Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
14.76
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Takeda's Dengue Vaccine Candidate Under FDA Priority Review
November 23, 2022
Via
Benzinga
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
November 22, 2022
This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result...
Via
Benzinga
Why Puma Biotechnology's Shares Jumped 20% on Monday
November 21, 2022
It may have benefited from positive news about another company's drug candidate.
Via
The Motley Fool
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
November 17, 2022
Via
Benzinga
2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade
November 16, 2022
Is now the time to load up on these high-yielding investments?
Via
The Motley Fool
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
November 02, 2022
The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.
Via
The Motley Fool
Takeda Posts Lower 1H Profit, Lifts FY22 Outlook
October 27, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
October 19, 2022
On Wednesday, 200 companies hit new 52-week lows.
Via
Benzinga
Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids
October 05, 2022
Via
Benzinga
Earnings Scheduled For October 27, 2022
October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Via
Benzinga
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
July 21, 2022
Via
Benzinga
7 Dividend Stocks to Sell Pronto Before a Painful Downturn
October 24, 2022
Investors may find many dividend stocks to sell, considering returns from the risk-free U.S. Treasury Bills often exceed their yield.
Via
InvestorPlace
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
3 High-Yielding Dividend Stocks Near Their 52-Week Lows
October 19, 2022
These stocks all pay far higher than the S&P 500 average dividend yield of 1.8%.
Via
The Motley Fool
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
September 21, 2022
Via
Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
September 16, 2022
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.
Via
Investor's Business Daily
7 Stocks Under $15 to Buy and Hold Forever
September 01, 2022
For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul.
Via
InvestorPlace
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 30, 2022
Via
Benzinga
Y-mAbs Gets Regulatory Approval In Israel For Neuroblastoma Candidate
August 30, 2022
The Israeli Ministry of Health has approved Y-mAbs Therapeutics’ (NASDAQ: YMAB) lead drug DANYELZA in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of...
Via
Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
August 30, 2022
Via
Benzinga
Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26
August 26, 2022
CNBC The Aviation Sector Is Slammed By Sky-High Rents
Via
Benzinga
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
August 26, 2022
Via
Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 22, 2022
Via
Benzinga
Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried
August 22, 2022
Shares hit their lowest point since November on the FDA's decision in HAE.
Via
Investor's Business Daily
Peering Into Takeda Pharmaceutical's Recent Short Interest
August 08, 2022
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has risen 18.18% since its last report. The company recently reported that it has 4.18 million shares sold...
Via
Benzinga
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets
July 27, 2022
BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome...
Via
Benzinga
Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents
July 26, 2022
Via
Benzinga
Peering Into Takeda Pharmaceutical's Recent Short Interest
July 21, 2022
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 15.38% since its last report. The company recently reported that it has 3.29 million shares sold short, which...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022
July 19, 2022
Upgrades
Via
Benzinga
Nestle Bets €40M On Enterome's Preclinical Food Allergy, IBD Hopeful
July 18, 2022
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.